The correlation of high TRAF1 expression with high cellular resistance to endoxifen treatment observed in YRI LCLs, and the knocking down of TRAF1 resulting in increased TAM sensitivity in breast cancer cell line both support this hypothesis. This evidence concerns the gene TRAF1 and breast carcinoma.